Axonics, Inc. (NASDAQ:AXNX) Shares Sold by Natixis

Natixis decreased its holdings in shares of Axonics, Inc. (NASDAQ:AXNX) by 26.7% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,418 shares of the company’s stock after selling 3,068 shares during the quarter. Natixis’ holdings in Axonics were worth $581,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Headlands Technologies LLC raised its position in shares of Axonics by 31.1% in the 1st quarter. Headlands Technologies LLC now owns 1,117 shares of the company’s stock worth $77,000 after buying an additional 265 shares during the period. NBC Securities Inc. raised its position in shares of Axonics by 106.4% in the 4th quarter. NBC Securities Inc. now owns 673 shares of the company’s stock worth $41,000 after buying an additional 347 shares during the period. Scholtz & Company LLC raised its position in shares of Axonics by 7.8% in the 4th quarter. Scholtz & Company LLC now owns 4,985 shares of the company’s stock worth $310,000 after buying an additional 360 shares during the period. Whittier Trust Co. raised its position in shares of Axonics by 59.1% in the 1st quarter. Whittier Trust Co. now owns 1,142 shares of the company’s stock worth $79,000 after buying an additional 424 shares during the period. Finally, Swiss National Bank raised its position in shares of Axonics by 0.6% in the 1st quarter. Swiss National Bank now owns 100,000 shares of the company’s stock worth $6,897,000 after buying an additional 600 shares during the period. Institutional investors and hedge funds own 99.48% of the company’s stock.

Axonics Stock Up 0.4 %

NASDAQ:AXNX traded up $0.28 during mid-day trading on Friday, reaching $68.47. The stock had a trading volume of 25,013 shares, compared to its average volume of 860,242. Axonics, Inc. has a 1-year low of $48.30 and a 1-year high of $69.68. The stock’s 50 day simple moving average is $67.45 and its two-hundred day simple moving average is $67.74.

Axonics (NASDAQ:AXNX) last posted its quarterly earnings results on Tuesday, April 30th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.32). The firm had revenue of $91.41 million during the quarter, compared to analyst estimates of $89.79 million. Axonics had a negative return on equity of 2.58% and a negative net margin of 4.12%. The firm’s revenue for the quarter was up 29.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.19) earnings per share. Sell-side analysts predict that Axonics, Inc. will post 0.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reissued a “hold” rating on shares of Axonics in a research report on Monday, May 6th. Eight analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, Axonics has an average rating of “Hold” and a consensus price target of $69.78.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.